Patient Leaflet Updated 04-Sep-2024 | Celltrion Healthcare UK Limited
Omlyclo 75mg Solution for Injection in pre-filled syringe
Omlyclo 75 mg solution for injection in pre-filled syringe
omalizumab
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side affects you may get. See the end of section 4 for how to report side effects.
1. What Omlyclo is and what it is used for
2. What you need to know before you use Omlyclo
3. How to use Omlyclo
4. Possible side effects
5. How to store Omlyclo
6. Contents of the pack and other information
Omlyclo contains the active substance omalizumab. Omalizumab is a man-made protein that is similar to natural proteins produced by the body. It belongs to a class of medicines called monoclonal antibodies.
Omlyclo is used for the treatment of:
Allergic asthma
This medicine is used to prevent asthma from getting worse by controlling symptoms of severe allergic asthma in adults, adolescents and children (6 years of age and older) who are already receiving asthma medicine, but whose asthma symptoms are not well controlled by medicines such as high-dose steroid inhalers and beta-agonist inhalers.
Chronic rhinosinusitis with nasal polyps
This medicine is used to treat chronic rhinosinusitis with nasal polyps in adults (18 years of age and older) who are already receiving intranasal corticosteroids (corticosteroid nasal spray), but whose symptoms are not well controlled by these medicines. Nasal polyps are small growths on the lining of the nose. Omlyclo helps to reduce the size of the polyps and improves symptoms including nasal congestion, loss of sense of smell, mucus in the back of the throat and runny nose.
Omlyclo works by blocking a substance called immunoglobulin E (IgE), which is produced by the body. IgE contributes to a type of inflammation that plays a key role in causing allergic asthma and chronic rhinosinusitis with nasal polyps.
If you think you may be allergic to any of the ingredients, tell your doctor as you should not use Omlyclo.
Talk to your doctor before using Omlyclo:
Omlyclo does not treat acute asthma symptoms, such as a sudden asthma attack. Therefore Omlyclo should not be used to treat such symptoms.
Omlyclo is not meant to prevent or treat other allergy-type conditions, such as sudden allergic reactions, hyperimmunoglobulin E syndrome (an inherited immune disorder), aspergillosis (a fungus-related lung disease), food allergy, eczema or hay fever because Omlyclo has not been studied in these conditions.
Omlyclo can potentially cause serious side effects. You must look out for signs of these conditions while you use Omlyclo. Seek medical help immediately if you notice any signs indicating a severe allergic reaction or other serious side effects. Such signs are listed under “Serious side effects” in section 4.
It is important that you receive training from your doctor in how to recognise early symptoms of severe allergic reactions, and how to manage these reactions if they occur, before you inject Omlyclo yourself or before a non-healthcare professional gives you a Omlyclo injection (see section 3, “How to use Omlyclo”). The majority of severe allergic reactions occur within the first 3 doses of Omlyclo.
Allergic asthma
Omlyclo is not recommended for children under 6 years of age. Its use in children under 6 years of age has not been studied.
Chronic rhinosinusitis with nasal polyps
Omlyclo is not recommended for children and adolescents under 18 years of age. Its use in patients under 18 years of age has not been studied.
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
This is especially important if you are taking:
If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine. Your doctor will discuss with you the benefits and potential risks of using this medicine during pregnancy.
If you become pregnant while being treated with Omlyclo, tell your doctor immediately.
Omlyclo may pass into breast milk. If you are breast-feeding or plan to breast-feed, ask your doctor for advice before using this medicine.
It is unlikely that Omlyclo will affect your ability to drive and use machines.
Always use this medicine exactly as your doctor has told you. Check with your doctor, nurse or pharmacist if you are not sure.
Omlyclo is used as an injection under your skin (known as a subcutaneous injection).
Injecting Omlyclo
For detailed instructions on how to inject Omlyclo, see “Instructions for use of Omlyclo pre-filled syringe” at the end of this leaflet.
Training to recognise serious allergic reactions
It is also important that you do not inject Omlyclo yourself until you have been trained by your doctor or nurse on:
For more information about the early signs and symptoms of serious allergic reactions, see section 4.
Your doctor will decide how much Omlyclo you need and how often you will need it. This depends on your body weight and the results of a blood test carried out before the start of the treatment to measure the amount of IgE in your blood.
You will need 1 to 4 injections at a time. You will need the injections either every two weeks, or every four weeks.
Keep taking your current asthma and/or nasal polyps medicine during Omlyclo treatment. Do not stop taking any asthma and/or nasal polyps medicine without talking to your doctor.
You may not see an immediate improvement after beginning Omlyclo treatment. In patients with nasal polyps effects have been seen 4 weeks after the start of the treatment. In asthma patients it usually takes between 12 and 16 weeks to have the full effect.
Allergic asthma
Omlyclo can be used in children and adolescents aged 6 years and older, who are already receiving asthma medicine, but whose asthma symptoms are not well controlled by medicines such as high dose steroid inhalers and beta-agonist inhalers. Your doctor will work out how much Omlyclo your child needs and how often it needs to be given. This will depend on your child’s weight and the results of a blood test carried out before the start of the treatment to measure the amount of IgE in his/her blood.
Children (6 to 11 years of age) are not expected to self-administer Omlyclo. However, if considered appropriate by their doctor, a caregiver may give them their Omlyclo injection after proper training.
Chronic rhinosinusitis with nasal polyps
Omlyclo should not be used in children and adolescents under 18 years of age.
If you have missed an appointment, contact your doctor or hospital as soon as possible to re-schedule it.
If you have forgotten to give yourself a dose of Omlyclo, inject the dose as soon as you remember. Then talk to your doctor to discuss when you should inject the next dose.
Do not stop treatment with Omlyclo unless your doctor tells you to. Interrupting or stopping the treatment with Omlyclo may cause your symptoms to come back.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects caused by Omlyclo are usually mild to moderate but can occasionally be serious.
Serious side effects:
Seek medical attention immediately if you notice any signs of the following side effects:
Rare (may affect up to 1 in 1000 people)
Not known (frequency cannot be estimated from the available data)
Other side effects include:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Rare (may affect up to 1 in 1000 people)
Not known (frequency cannot be estimated from the available data)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
Omlyclo solution for injection is supplied as a clear to cloudy, colourless to pale brownish-yellow solution in a pre-filled syringe.
Omlyclo 75 mg solution for injection is available in a pack containing 1 pre-filled syringe
For any information about this medicine, please contact the Marketing Authorisation Holder:
This leaflet was last revised in 07/2024
Read and follow the Instructions for Use that come with your Omlyclo Pre-filled Syringe before you start using it and each time you get a refill. There may be new information.
This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
Children (6 to less than 12 years of age) should not inject Omlyclo Pre-filled Syringes themselves, however, if deemed appropriate by their healthcare provider, a caregiver may give them their injection after proper training.
Omlyclo Pre-filled Syringes are available in 2 dose strengths (see Figure A). These instructions are to be used for the 75 mg/0.5 mL dose strength. The type of Pre-filled Syringe you receive depends on the dose prescribed by your healthcare provider (see Figure C: Dosing Chart). Check the label on the carton and the color of the Plunger rod to make sure that the dose strength is correct.
1. Gather the supplies for the injection
1.a. Prepare a clean, flat surface, such as a table or countertop, in a well-lit area.
1.b. Take the carton(s) containing the Prefilled Syringe(s) needed to administer your prescribed dose out of the refrigerator.
Note: Depending on the dose prescribed to you by your healthcare provider you may need to prepare one or more Pre-filled Syringes and inject the contents of them all. The following chart shows how many injections of each dose strength are needed for your prescribed dose (see Figure C: Dosing Chart).
1.c. Make sure you have the following supplies:
Not included in the carton:
2. Check the expiration on the carton (see Figure D).
3. Wait 30 minutes.
3.a. Leave the unopened carton containing the Pre-filled Syringe at room temperature (25°C) for 30 minutes to allow it to warm up (see Figure E).
4. Wash your hands.
4.a. Wash your hands with soap and water and dry them thoroughly (see Figure F).
5. Choose an injection site (see Figure G)
5.a. You may inject into:
5.b. Choose a different injection site for each new injection at least 2.5 cm away from the area used for the last injection.
6. Clean the injection site.
6.a. Clean the injection site with an alcohol swab using a circular motion (see Figure H).
6.b. Let the skin dry before injecting.
7. Inspect the Pre-filled Syringe.
7.a. Open the carton.
Gripping from the syringe body lift the Pre-filled Syringe from the tray.
7.b. Look at the Pre-filled Syringe and make sure you have the correct Medicine (Omlyclo) and dosage.
7.c. Look at the Pre-filled Syringe and make sure it is not cracked or damaged.
7.d. Check the expiration date on the label of the Pre-filled Syringe (see Figure I).
Note: If the expiration date is not visible in the viewing window, you may rotate the inner barrel of the Pre-filled Syringe until the expiration date becomes visible.
8. Inspect the Medicine.
8.a. Look at the Medicine and confirm that the liquid is clear to cloudy, colourless to pale brownish-yellow, and free of particles (see Figure J).
9. Remove the Cap.
9.a. Hold the Pre-filled Syringe by the syringe body in one hand. Gently pull the Cap straight off with the other hand.
9.b. Dispose of the Cap right away in a sharps disposal container (see step 13. Dispose of the Pre-filled Syringe and Figure K).
10. Insert the Pre-filled Syringe into the injection site.
10.a. Gently pinch a fold of skin at the injection site with one hand.
Note: Pinching the skin is important to make sure that you inject under the skin (into the fatty area) but not any deeper (into muscle).
10.b. With a quick and “dart-like” motion, insert the Needle completely into the fold of skin at a 45 to 90-degree angle (see Figure L).
11. Give the injection.
11.a. After the Needle is inserted, release the pinch.
11.b. Slowly push the Plunger rod all the way down until the full dose of medicine gets injected, and the syringe is empty (see Figure M).
12. Remove the Pre-filled Syringe from the injection site.
12.a. After the Pre-filled Syringe is empty, slowly lift your thumb from the Plunger rod until the Needle is completely covered by the Needle Guard (see Figure N).
13. Dispose of the Pre-filled Syringe.
13.a. Put the used Pre-filled Syringe in a sharps disposal container right away after use (see Figure O).
14. Care for the injection site.
14.a. If some bleeding occurs, treat the injection site by gently pressing, not rubbing, a cotton ball or gauze to the site and apply an adhesive bandage if needed.
Celltrion Healthcare UK Limited, The Switch, 1-7 The Grove, Slough, Berkshire, SL1 1QP
01753 983 500
http://www.celltrionhealthcare.co.uk/
01753 983 500
01753 983 500